首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi 以基因為基之藥物開發

市場調查報告書

商品編碼

1419131

基因編輯市場規模和預測、全球和地區佔有率、趨勢和成長機會分析報告範圍：按組件、技術、應用、最終用戶和地理位置

Gene Editing Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Component, Technology, Application, End User, and Geography

出版日期: 2023年12月05日 | 出版商:

The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格

簡介目錄

基因編輯市場規模預計將從2022年的65.42億美元成長到2030年的239.02億美元；預計2022-2030年CAGR為17.6%。

基因編輯市場的成長歸因於癌症和其他遺傳疾病的增加以及基因研究投資的增加。然而，基因組設備的高成本阻礙了市場的成長。

個人化醫療是利用患者的遺傳和環境資料提供最佳醫療保健的領域。它基於每個患者都是獨特的並且需要個別化藥物治療的原則。由於它是一個快速發展的領域，目前已涵蓋多個醫療保健系統。對基因組進行精確改變的能力為開發標靶療法和個人化醫療開闢了新的可能性。基因編輯在個人化醫療中至關重要，它可以根據患者的遺傳訊息為個別患者量身定做治療方案。它提供了該領域的各種應用。首先，像 CRISPR-Cas9 這樣的基因編輯技術可以糾正或修改與遺傳性疾病相關的特定基因，從而有可能為囊性纖維化和其他遺傳性疾病等疾病提供治療或治癒方法。其次，基因編輯有助於藥物基因組學，使研究人員能夠研究個體的遺傳變異如何影響他們的藥物反應。這些知識有助於制定個人化治療計劃和最佳化藥物劑量。

基因編輯在個人化癌症治療中也顯示出前景，可以編輯免疫細胞以更好地瞄準和摧毀癌細胞。此外，基因編輯可以透過增強免疫細胞識別和改變病原體來預防和治療傳染病。它還透過創建準確的疾病模型來促進疾病建模和藥物開發，使研究人員能夠更好地了解疾病並開發個人化的治療方法。這些應用展示了基因編輯在推進個人化醫療方面的潛力，從而實現針對個別基因譜的客製化治療。個人化醫療中的基因編輯仍在推進，需要進一步的研究和臨床試驗來確保安全性和有效性。

對個人化醫療日益成長的需求是推動基因編輯市場成長的主要因素之一。基因編輯技術使得基於個體基因組成的客製化療法和治療成為可能。 2021 年 7 月，美國 FDA 授權一名患者接受基於 CRISPR 的基因突變客製化治療。波士頓非營利性治癒罕見疾病組織啟動了這項臨床試驗，該試驗標誌著許多里程碑，包括首次個人化 CRISPR 療法和首次實施任何形式的基因編輯治療肌肉營養不良症的臨床試驗。

透過這種個人化的醫療方法，可以提高患者的健康水平、減少不良反應並獲得更好的治療結果。對標靶治療的需求和對個人化醫療的日益了解是基因編輯技術採用和發展的主要因素。正在開發的基因治療候選藥物數量不斷增加，凸顯了個人化醫療和治療以前無法治癒的疾病方面實現變革性突破的潛力，有利於市場成長。

生產成本取決於不同參與者提供的不同應用的基因組編輯包。與基因編輯設備相關的成本可能很高。 CRISPR-Cas9 等基因編輯技術需要專門的實驗室設備，包括 DNA 定序儀、熱循環儀、螢光顯微鏡和電穿孔設備。這些儀器的價格很高，從數千美元到數百萬美元不等。美國食品藥物管理局 (FDA) 已批准四種基因治療方法。 Kymriah 和 Yescarta 是兩種嵌合抗原受體（CAR T 細胞）治療方法。 Yescarta 的市場價格為 373,000 美元，而 Kymriah 的價格在 373,000 美元至 475,000 美元之間，具體取決於癌症類型。 FDA 於 2017 年批准 Luxturna 用於治療一種罕見的遺傳性失明，該疾病影響了美國 1,000 至 2,000 人。該手術的費用為每隻眼睛 425,000 美元。 Zolgensma 於 2020 年獲得許可，用於治療兩歲以下兒童的一種罕見的兒童疾病，稱為脊髓性肌肉萎縮症。每位患者一次靜脈注射的費用為 210 萬美元。生產成本隨著生產過程中增加的工序而增加。

此外，基因組編輯方法的驗證和評估還有額外的挑戰和成本。如果驗證顯示負面結果，則會執行重複的程序，並在相同的程序上花費數百和數千美元。因此，在基因組編輯產生的總成本中，三分之二用於驗證。因此，生產成本是限制市場成長的主要因素之一。

基於組件的見解

根據組件，基因編輯市場分為試劑和耗材、軟體和系統以及服務。 2022 年，服務細分市場佔據最大市場佔有率。然而，預計 2022 年至 2030 年，試劑和消耗品細分市場的CAGR最高。

國際癌症研究機構和世界衛生組織（WHO）是準備基因編輯市場報告時參考的主要和次要來源之一。

歐洲
- 德國
- 法國
- 義大利
- 西班牙
- 英國
- 歐洲其他地區
亞太
- 澳洲
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
南美洲和中美洲
- 巴西
- 阿根廷
- 南美洲和中美洲其他地區

第 12 章：產業格局

併購
協議、合作、合資企業
新產品發布
擴張和其他策略發展

第13章：競爭格局

關鍵參與者的熱圖分析
公司定位與專注

第 14 章：基因編輯市場 - 主要公司概況

Thermo Fisher Scientific Inc.

注意 - 將為以下公司列表提供類似資訊

默克公司
龍沙
金斯瑞
CRISPR療法
珀金埃爾默公司
安捷倫科技
精密生物科學
桑加莫治療公司
新英格蘭生物實驗室
諾華公司

第 15 章：附錄

詞彙表
關於 Insight Partners
市場情報雲

簡介目錄

Product Code: TIPRE00032626

The gene editing market size is expected to grow from US$ 6.542 billion in 2022 to US$ 23.902 billion by 2030; it is estimated to record a CAGR of 17.6% during 2022-2030.

The growth of the gene editing market is attributed to the increase in cancer and other genetic disorders and growing investment in genetic research. However, the high cost of genomic equipment hinders the market growth.

Personalized medicine is the field that utilizes patients' genetic and environmental data to deliver optimal healthcare. It is based on the principle that every patient is unique and requires individualistic pharmacological treatment. Since it is a rapidly evolving area, it is presently incorporated into several healthcare systems. The ability to make precise changes in the genome opens new possibilities for developing targeted therapies and personalized medicine. Gene editing is crucial in personalized medicine by tailoring medical treatments to individual patients based on their genetic information. It offers various applications in the field. Firstly, gene editing techniques like CRISPR-Cas9 enable the correction or modification of specific genes associated with genetic disorders, potentially providing treatments or cures for conditions such as cystic fibrosis and other genetic disorders. Secondly, gene editing aids in pharmacogenomics, allowing researchers to study how an individual's genetic variation impacts their medication response. This knowledge helps in developing personalized treatment plans and optimizing drug dosage.

Gene editing has also shown promise in personalized cancer therapy, where immune cells can be edited to better target and destroy cancer cells. Furthermore, gene editing can contribute to preventing and treating infectious diseases by enhancing immune cell recognition and modifying pathogens. It also facilitates disease modeling and drug development by creating accurate disease models, enabling researchers to understand diseases better and develop personalized treatment approaches. These applications demonstrate the potential of gene editing in advancing personalized medicine, enabling tailored treatments specific to an individual genetic profile. Gene editing in personalized medicine is still advancing, and further research and clinical trials are needed to ensure safety and efficacy.

The growing need for personalized medicine is one of the main factors propelling the growth of the gene editing market. Gene editing technology makes customized therapies and treatments based on an individual's genetic composition possible. In July 2021, the US FDA authorized one patient to receive a tailored CRISPR-based gene therapy for their mutation. The Boston non-profit Cure Rare Disease initiated the clinical trial, which marked numerous milestones, including the first-ever personalized CRISPR therapy and the first clinical trial to implement any form of gene editing for muscular dystrophy treatment.

Increased patient well-being, fewer adverse effects, and better treatment outcomes are all possible with this personalized approach to medicine. The demand for targeted therapeutics and the increasing understanding of personalized medicine have been major factors in the uptake and development of gene editing technology. The growing number of gene therapy candidates in the development pipeline highlights the potential for transformative breakthroughs in personalized medicine and treating previously incurable diseases, favoring market growth.

The cost of production is determined by the packages of genome editing for different applications offered by different players. The costs associated with gene editing equipment can be substantial. Gene editing technologies like CRISPR-Cas9 require specialized laboratory equipment, including DNA sequencers, thermal cyclers, fluorescence microscopes, and electroporation devices. These instruments have a high price tag, ranging from thousands to millions of dollars. The US Food and Drug Administration (FDA) has authorized four gene treatments. Kymriah and Yescarta are two chimeric antigen receptor (CAR T-cell) treatments. Yescarta costs US$ 373,000 in the market, whereas Kymriah costs between US$ 373,000 and US$ 475,000, depending on the kind of cancer. The FDA licensed Luxturna in 2017 to treat a rare kind of inherited blindness that affects 1,000 to 2,000 people in the US. The cost of this procedure is US$ 425,000 per eye. Zolgensma was licensed in 2020 to treat a rare childhood condition called spinal muscular atrophy in children under the age of two. Per patient, a single intravenous injection costs US$ 2.1 million. The cost of production is increased based on the procedures added during the production.

In addition, additional challenges and costs are associated with the validation and evaluation of genome editing methods. If the validation shows negative results, repetitive procedures are performed, and hundreds and thousands of dollars are spent on the same procedures. Thus, out of the total cost incurred in the production of genome editing, two-thirds is spent on validation. Hence, the cost of production is among the primary factors restraining the market's growth.

Components-Based Insights

Based on components, the gene editing market is segmented into reagents and consumables, software and systems, and services. The services segment dominated with the largest share of the market in 2022. However, the reagents and consumables segment is anticipated to register the highest CAGR from 2022 to 2030.

The International Agency for Research on Cancer and the World Health Organization (WHO) are among the primary and secondary sources referred to while preparing the gene editing market report.

1. Introduction

1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness Analysis

3. Research Methodology

4. Gene Editing Market Landscape

4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain

5. Gene Editing Market - Key Market Dynamics

5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints

6. Gene Editing Market - Global Market Analysis

6.1 Gene Editing - Global Market Overview
6.2 Gene Editing - Global Market and Forecast to 2030

7. Gene Editing Market - Revenue Analysis (USD Million) - By Technology, 2020-2030

7.1 Overview
7.2 Clustered Regularly Interspaced Short Palindromic Repeats
7.3 Transcription Activator-Like Effector Nucleases
7.4 Zinc Finger Nucleases
7.5 Other Technologies

8. Gene Editing Market - Revenue Analysis (USD Million) - By Component, 2020-2030

8.1 Overview
8.2 Reagents and Consumables
8.3 Software and Systems
8.4 Services

9. Gene Editing Market - Revenue Analysis (USD Million) - By Application, 2020-2030

9.1 Overview
9.2 Clinical Applications
9.3 Genetic Engineering

10. Gene Editing Market - Revenue Analysis (USD Million) - By End User, 2020-2030

10.1 Overview
10.2 Pharmaceutical Companies and Biotechnology Companies
10.3 Academics and Government Research Institutes
10.4 Clinical Research Organizations

11. Gene Editing Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

11.1 North America
- 11.1.1 North America Gene Editing Market Overview
- 11.1.2 North America Gene Editing Market Revenue and Forecasts to 2030
- 11.1.3 North America Gene Editing Market Revenue and Forecasts and Analysis - By Technology
- 11.1.4 North America Gene Editing Market Revenue and Forecasts and Analysis - By Component
- 11.1.5 North America Gene Editing Market Revenue and Forecasts and Analysis - By Application
- 11.1.6 North America Gene Editing Market Revenue and Forecasts and Analysis - By End User
- 11.1.7 North America Gene Editing Market Revenue and Forecasts and Analysis - By Countries
  - 11.1.7.1 United States Gene Editing Market
    - 11.1.7.1.1 United States Gene Editing Market, by Technology
    - 11.1.7.1.2 United States Gene Editing Market, by Component
    - 11.1.7.1.3 United States Gene Editing Market, by Application
    - 11.1.7.1.4 United States Gene Editing Market, by End User
  - 11.1.7.2 Canada Gene Editing Market
    - 11.1.7.2.1 Canada Gene Editing Market, by Technology
    - 11.1.7.2.2 Canada Gene Editing Market, by Component
    - 11.1.7.2.3 Canada Gene Editing Market, by Application
    - 11.1.7.2.4 Canada Gene Editing Market, by End User
  - 11.1.7.3 Mexico Gene Editing Market
    - 11.1.7.3.1 Mexico Gene Editing Market, by Technology
    - 11.1.7.3.2 Mexico Gene Editing Market, by Component
    - 11.1.7.3.3 Mexico Gene Editing Market, by Application
    - 11.1.7.3.4 Mexico Gene Editing Market, by End User

Note - Similar analysis would be provided for below mentioned regions/countries

11.2 Europe
- 11.2.1 Germany
- 11.2.2 France
- 11.2.3 Italy
- 11.2.4 Spain
- 11.2.5 United Kingdom
- 11.2.6 Rest of Europe
11.3 Asia-Pacific
- 11.3.1 Australia
- 11.3.2 China
- 11.3.3 India
- 11.3.4 Japan
- 11.3.5 South Korea
- 11.3.6 Rest of Asia-Pacific
11.4 Middle East and Africa
- 11.4.1 South Africa
- 11.4.2 Saudi Arabia
- 11.4.3 U.A.E
- 11.4.4 Rest of Middle East and Africa
11.5 South and Central America
- 11.5.1 Brazil
- 11.5.2 Argentina
- 11.5.3 Rest of South and Central America

12. Industry Landscape

12.1 Mergers and Acquisitions
12.2 Agreements, Collaborations, Joint Ventures
12.3 New Product Launches
12.4 Expansions and Other Strategic Developments

13. Competitive Landscape

13.1 Heat Map Analysis by Key Players
13.2 Company Positioning and Concentration

14. Gene Editing Market - Key Company Profiles

14.1 Thermo Fisher Scientific Inc.
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments

Note - Similar information would be provided for below list of companies